Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%

NCT03351842 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT03351842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03351842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2017
Completion date
September 1, 2024
Enrollment
460 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, adjuvant, histological type of neoplasm, lung adenocarcinoma, stage i, treatment